

Title (en)
PRO-NEUROGENIC COMPOUNDS

Title (de)
PRO-NEUROGENE VERBINDUNGEN

Title (fr)
COMPOSÉS PRO-NEUROGÈNES

Publication
EP 2925129 A4 20160608 (EN)

Application
EP 12883358 A 20120824

Priority
• US 2012052283 W 20120824
• US 201213594223 A 20120824

Abstract (en)
[origin: WO2014031125A1] This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

IPC 8 full level
A01N 43/38 (2006.01); **A61K 31/405** (2006.01); **C07D 209/82** (2006.01)

CPC (source: EP)
A61P 9/10 (2017.12); **A61P 21/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/02** (2017.12); **A61P 25/08** (2017.12); **A61P 25/14** (2017.12); **A61P 25/16** (2017.12); **A61P 25/18** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 25/30** (2017.12); **A61P 25/36** (2017.12); **A61P 27/00** (2017.12); **A61P 27/02** (2017.12); **C07D 209/86** (2013.01); **C07D 209/88** (2013.01); **C07D 401/06** (2013.01); **C07D 403/06** (2013.01); **C07D 405/12** (2013.01); **C07D 413/06** (2013.01); **C07D 471/04** (2013.01); **C07D 495/04** (2013.01)

Citation (search report)
• [X] US 2011003836 A1 20110106 - MCKNIGHT STEVEN L [US], et al
• [X] US 2010022580 A1 20100128 - HUNG DAVID T [US], et al
• [A] WO 02060867 A2 20020808 - INSIGHT STRATEGY AND MARKETING [IL], et al
• [X] KAREN S. MACMILLAN ET AL: "Development of Proneurogenic, Neuroprotective Small Molecules", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, no. 5, 9 February 2011 (2011-02-09), pages 1428 - 1437, XP055039500, ISSN: 0002-7863, DOI: 10.1021/ja108211m
• [X] ANDREW A. PIEPER ET AL: "Discovery of a Proneurogenic, Neuroprotective Chemical", CELL, vol. 142, no. 1, 1 July 2010 (2010-07-01), pages 39 - 51, XP055099451, ISSN: 0092-8674, DOI: 10.1016/j.cell.2010.06.018
• See references of WO 2014031125A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2014031125 A1 20140227; AU 2012388221 A1 20150409; AU 2012388221 B2 20170831; AU 2017268635 A1 20171221; BR 112015003919 A2 20170704; CA 2882923 A1 20140227; CN 104754941 A 20150701; CN 104754941 B 20180227; CN 108329253 A 20180727; EP 2925129 A1 20151007; EP 2925129 A4 20160608; IL 237341 A0 20150430; JP 2015529663 A 20151008; JP 6231566 B2 20171115

DOCDB simple family (application)
US 2012052283 W 20120824; AU 2012388221 A 20120824; AU 2017268635 A 20171130; BR 112015003919 A 20120824; CA 2882923 A 20120824; CN 201280076645 A 20120824; CN 201810075183 A 20120824; EP 12883358 A 20120824; IL 23734115 A 20150222; JP 2015528446 A 20120824